STAC-9 is an experimental drug that was developed by GlaxoSmithKline as a small-molecule activator of the sirtuin subtype SIRT1, with potential applications in the treatment of diabetes.

[1][2][3]

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.